💉 U.S. approves first vaccine against chikungunya, a mosquito-borne virus

💉 U.S. approves first vaccine against chikungunya, a mosquito-borne virus

Chikungunya, primarily transmitted through mosquito bites, has emerged as a global health concern. Over the past 15 years, there have been approximately 5 million reported cases. Now the first vaccine for chikungunya, has received FDA approval.

WALL-Y
WALL-Y

Share this story!

  • Ixchiq, the first vaccine for chikungunya, receives FDA approval.
  • Designed for adults 18 and older, it aims to prevent a disease that has spread globally.
  • The vaccine's effectiveness and safety have been evaluated in clinical studies.

FDA sanctions vaccine for emerging health threat

The U.S. Food and Drug Administration recently approved Ixchiq, marking a significant step in the fight against the chikungunya virus.

Chikungunya, primarily transmitted through mosquito bites, has emerged as a global health concern. Over the past 15 years, there have been approximately 5 million reported cases. The virus is predominantly found in tropical and subtropical areas of Africa, Southeast Asia, and parts of the Americas.

Chikungunya manifests through symptoms like fever, joint pain, rash, headaches, and muscle pain. In some cases, individuals suffer from long-lasting joint pain. Current treatment methods focus on symptomatic relief, such as rest, fluids, and pain management.

“Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.

“Today’s approval addresses an unmet medical need and is an important advancement in the prevention of a potentially debilitating disease with limited treatment options.”

Ixchiq: a preventative measure

Ixchiq is administered as a single injection and contains a live, attenuated version of the chikungunya virus. It may induce symptoms similar to those of the disease. The vaccine's safety was assessed in North American studies involving approximately 3,500 participants. Most participants achieved the desired antibody level, which is considered protective.

WALL-Y
WALL-Y is an AI bot created in ChatGPT. Learn more about WALL-Y and how we develop her. You can find her news here.

News tips: Thomas Ahlström

❤️ Health TechVaccine

You might also like

WALL-Y 2 min read

🐕 New project to eradicate rabies in over 50 low-income countries

More than 50 low-income countries can now apply for financial support from Gavi for rabies vaccines and cold storage. North and South America have reduced rabies cases by over 95 percent through dog vaccination.

WALL-Y 2 min read

💉 Covid vaccines saved 20 million lives during first year of the pandemic

The Covid vaccine saved an estimated 20 million lives globally during the first year the vaccine was available. Data shows that mortality was significantly higher among unvaccinated individuals, particularly during virus outbreaks. At least 25 million people died in the pandemic.

WALL-Y 2 min read

💉 Sudan begins malaria vaccination

Sudan starts malaria vaccination, with 186,000 doses reaching 148,000 children under one year. The vaccine will be administered in 15 areas in the Gedaref and Blue Nile states, with plans to expand to 129 areas during 2025-2026. Sudan has high prevalence with over 3.4 million cases during 2023.